SMTI Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -13.19% compared to Sanara MedTech's net margin of --. Sanara MedTech's return on equity of -19.67% beat Perspective Therapeutics's return on equity of --.

Sanara MedTech has a consensus price target of $44.00, signalling upside risk potential of 28.99%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 414.33%. Given that Perspective Therapeutics has higher upside potential than Sanara MedTech, analysts believe Perspective Therapeutics is more attractive than Sanara MedTech.

Sanara MedTech has a beta of 1.574, which suggesting that the stock is 57.373% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Sanara MedTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Sanara MedTech quarterly revenues are $21.7M, which are larger than Perspective Therapeutics quarterly revenues of --. Sanara MedTech's net income of -$2.9M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Sanara MedTech's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech is 3.69x versus 16.96x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Daxor has a net margin of -13.19% compared to Sanara MedTech's net margin of --. Sanara MedTech's return on equity of -19.67% beat Daxor's return on equity of 5.22%.

Sanara MedTech has a consensus price target of $44.00, signalling upside risk potential of 28.99%. On the other hand Daxor has an analysts' consensus of -- which suggests that it could grow by 181.63%. Given that Daxor has higher upside potential than Sanara MedTech, analysts believe Daxor is more attractive than Sanara MedTech.

Sanara MedTech has a beta of 1.574, which suggesting that the stock is 57.373% more volatile than S&P 500. In comparison Daxor has a beta of -0.508, suggesting its less volatile than the S&P 500 by 150.824%.

Sanara MedTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daxor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech pays -- of its earnings as a dividend. Daxor pays out -- of its earnings as a dividend.

Sanara MedTech quarterly revenues are $21.7M, which are larger than Daxor quarterly revenues of --. Sanara MedTech's net income of -$2.9M is higher than Daxor's net income of --. Notably, Sanara MedTech's price-to-earnings ratio is -- while Daxor's PE ratio is 27.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech is 3.69x versus 15.35x for Daxor. Usually stocks with elevated PS ratios are considered overvalued.

Precision Optics has a net margin of -13.19% compared to Sanara MedTech's net margin of -31.24%. Sanara MedTech's return on equity of -19.67% beat Precision Optics's return on equity of -34.86%.

Sanara MedTech has a consensus price target of $44.00, signalling upside risk potential of 28.99%. On the other hand Precision Optics has an analysts' consensus of -- which suggests that it could fall by --. Given that Sanara MedTech has higher upside potential than Precision Optics, analysts believe Sanara MedTech is more attractive than Precision Optics.

Sanara MedTech has a beta of 1.574, which suggesting that the stock is 57.373% more volatile than S&P 500. In comparison Precision Optics has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.901%.

Sanara MedTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision Optics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech pays -- of its earnings as a dividend. Precision Optics pays out -- of its earnings as a dividend.

Sanara MedTech quarterly revenues are $21.7M, which are larger than Precision Optics quarterly revenues of $4.2M. Sanara MedTech's net income of -$2.9M is lower than Precision Optics's net income of -$1.3M. Notably, Sanara MedTech's price-to-earnings ratio is -- while Precision Optics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech is 3.69x versus 1.61x for Precision Optics. Usually stocks with elevated PS ratios are considered overvalued.

Warby Parker has a net margin of -13.19% compared to Sanara MedTech's net margin of -2.12%. Sanara MedTech's return on equity of -19.67% beat Warby Parker's return on equity of -10.25%.

Sanara MedTech has a consensus price target of $44.00, signalling upside risk potential of 28.99%. On the other hand Warby Parker has an analysts' consensus of $22.23 which suggests that it could fall by -11.33%. Given that Sanara MedTech has higher upside potential than Warby Parker, analysts believe Sanara MedTech is more attractive than Warby Parker.

Sanara MedTech has a beta of 1.574, which suggesting that the stock is 57.373% more volatile than S&P 500. In comparison Warby Parker has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sanara MedTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Warby Parker offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech pays -- of its earnings as a dividend. Warby Parker pays out -- of its earnings as a dividend.

Sanara MedTech quarterly revenues are $21.7M, which are smaller than Warby Parker quarterly revenues of $192.4M. Sanara MedTech's net income of -$2.9M is higher than Warby Parker's net income of -$4.1M. Notably, Sanara MedTech's price-to-earnings ratio is -- while Warby Parker's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech is 3.69x versus 4.04x for Warby Parker. Usually stocks with elevated PS ratios are considered overvalued.